Previous 10 | Next 10 |
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmac...
2024-04-12 04:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-22 13:55:54 ET Summary HilleVax, Inc. top line results from the phase 2/3 NEST-IN1 study, using HIL-214 for the prevention of Norovirus-related gastroenteritis, expected mid-2024. Several other studies have already been initiated using HIL-214 for the prevention of Norovir...
2024-03-20 17:04:40 ET More on HilleVax Seeking Alpha’s Quant Rating on HilleVax Historical earnings data for HilleVax Financial information for HilleVax Read the full article on Seeking Alpha For further details see: HilleVax GAAP EPS of -...
2024-03-20 17:02:59 ET More on HilleVax Seeking Alpha’s Quant Rating on HilleVax Read the full article on Seeking Alpha For further details see: HilleVax files $500M mixed securities shelf
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023 BOSTON, March 20, 2024 (GLOBE NEWSWIRE)...
Tredegar Corporation (TG) is expected to report for quarter end 2023-12-31 Pharma-Bio Serv Inc (PBSV) is expected to report $0.02 for Q1 2024 Telos Corporation (TLS) is expected to report $-0.18 for Q4 2023 Coretec Group Inc (CRTG) is expected to report for quarter end 2023-12-31 ...
2024-03-02 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-10 02:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6 th Annual Biotechnology Conference in New York, New York on We...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
85.92%Change Percent:
HilleVax Inc. Company Name:
HLVX Stock Symbol:
NASDAQ Market:
HilleVax Inc. Website:
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 35.3% to $0.3248 on volume of 164,333,109 shares SRIVARU Holding Limited (SVMH) rose 62.4% to $0.2581 on volume of 68,213,933 shares NVIDIA Corporation (NVDA) rose 2.9% to $129.43 on volume o...
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential for continued development of HIL-214 and HIL-216 in adults BOSTON, July 08, 2024 ...